DEF: Barinthus Biotherapeutics Sets Date for 2025 Annual General Meeting

Barinthus Biotherapeutics announces its 2025 Annual General Meeting to be held on June 10, 2025, in London.

Summary

• Barinthus Biotherapeutics plc will hold its 2025 Annual General Meeting on June 10, 2025, at 2:30 p.m. London Time at Goodwin Procter (UK) LLP, London.
• Shareholders will vote on eight ordinary resolutions, including the re-election of directors Pierre A. Morgon and Joseph C. Scheeren.
• The resolutions also cover the re-appointment and ratification of PricewaterhouseCoopers LLP as the company's auditors, authorization for the Audit Committee to determine auditor remuneration, and approval of the directors' remuneration policy and report.
• The Board of Directors recommends voting in favor of all resolutions.
• Only shareholders registered by 6:30 p.m. London Time on June 6, 2025, are entitled to vote.
• As of April 14, 2025, the company's issued ordinary share capital consisted of 40,399,395 ordinary shares.
• ADS holders will not be able to attend the Meeting in person.
• ADS voting instruction cards must be received by The Bank of New York Mellon Corporation no later than 12:00 p.m. Eastern Time on June 4, 2025.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, with a positive tone from the Chairman expressing gratitude. The Board's recommendation to vote in favor of all resolutions suggests confidence in the company's direction.

Positives

• The Board of Directors unanimously recommends voting in favor of all resolutions, indicating confidence in the company's direction.
• The meeting provides an opportunity for shareholders to engage with the company's leadership and express their views.
• The company is using the Internet as the primary means of providing proxy materials to beneficial holders of ADSs, which is more environmentally friendly and reduces costs.

Future Outlook

The Board of Directors intends for the Directors Compensation Policy to apply for three years from the date of approval at the 2025 Annual General Meeting.

Management Comments

• Robin Wright, Chairman, expresses gratitude for shareholders' ongoing support.
• The Board of Directors considers each resolution to be in the best interests of the Company and its shareholders.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the holding of annual general meetings, election of directors, and appointment of auditors. The compensation disclosures align with regulatory requirements for transparency.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is typical for biotech companies of similar size and stage.
• The use of independent compensation consultants like Aon is a common practice to ensure competitive and fair compensation packages.
• The audit fee structure and pre-approval policy are consistent with industry best practices and regulatory requirements for auditor independence.
• The inclusion of a clawback policy aligns with recent SEC regulations and industry trends in executive compensation.

Related Party Transactions

• In April 2020, we entered into the OUI License Agreement Amendment with Oxford University Innovation Limited (OUI) in respect of our rights to the ChAdOx1 technology in COVID-19 vaccines to facilitate the license of those rights by OUI to AstraZeneca.
• During the year ended December 31, 2024, we recognized $15.0 million in revenue and the Company was owed $nil from OUI as of December 31, 2024.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights and the potential influence on company decisions.
• Employees are indirectly impacted through the approval of director remuneration policies and the overall governance of the company.
• The company's performance and governance practices can affect its relationships with customers, suppliers, and creditors.

Next Steps

• Shareholders should review the proxy materials and vote on the resolutions.
• The company will hold the Annual General Meeting on June 10, 2025.
• The company will announce the voting results via a Form 8-K filing with the SEC.

Key Dates

Keywords

Annual General Meeting, Shareholders, Board of Directors, Proxy Statement, Resolutions, Auditors, Remuneration, Directors, Voting, Barinthus Biotherapeutics